Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 32%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is expected to continue its positive growth trajectory with the launch and approval of its Mobi Tubeless patch pump in 2026, along with a strong focus on the pharmacy channel. The company's projected weighted average gross margin and year-over-year revenue growth indicate potential for improved profitability and increased market share. While there may be some revenue challenges in the near future, successful execution of their plans could result in faster profit growth. Risks to the upside include gaining more market share and successfully entering the pharmacy channel.

Bears say

Tandem Diabetes Care is facing pressure from competitors in the market for insulin pumps and infusion sets, as well as potential execution risks related to converting patients to the pharmacy channel. Although the company's recent launch of its smaller Mobi pump and continued development of Tobi and Sigi could drive sales, the majority of Tandem's revenue comes from the US, limiting its potential for global growth. The company has also struggled in recent quarters with meeting revenue guidance and there are potential risks related to product development timelines and new product introductions. Additionally, the current valuation for Tandem is relatively low compared to its peers, but a successful transition to a pay-as-you-go model could drive higher recurring revenues and profit in the future.

TNDM has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 32% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 19 analysts, TNDM has a Buy consensus rating as of Jul 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.